These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9200958)

  • 1. Ki-67 as a marker of proliferation activity in tumor progression of recurrent gliomas of supratentorial localization. Immunocytochemical quantitative studies.
    Kałuza J; Adamek D; Pyrich M
    Pol J Pathol; 1997; 48(1):31-6. PubMed ID: 9200958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCNA and protein P53 in recurrent supratentorial glial brain tumors: studies on correlation between morphology and tumor progression.
    Kałuza J; Adamek D; Pyrich M
    Pol J Pathol; 1995; 46(3):155-61. PubMed ID: 7496734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
    Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
    Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of gliomas by morphological and immunocytochemical analysis in cell cultures.
    Fazekas I; Kerekes E; Hegedús B; Nyáry I
    Ideggyogy Sz; 2002 May; 55(5-6):173-9. PubMed ID: 12122877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
    Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
    Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer.
    Oshima CT; Iriya K; Forones NM
    Neoplasma; 2005; 52(5):420-4. PubMed ID: 16151588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of Ki-67 in childhood low-grade glioma.
    Maurizi P; Ruggiero A; Attinà G; Cefalo MG; Arlotta A; Riccardi R
    Pediatr Med Chir; 2008; 30(2):73-8. PubMed ID: 18581959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
    Lavertu P; Adelstein DJ; Myles J; Secic M
    Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of prognostic markers in brain tumors.
    Grzybicki DM; Moore SA
    Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cellular kinetics of cerebral glioma: study of the proliferative activity using monoclonal antibody Ki 67. Apropos of 60 cases].
    Parent M; Blond S; Gosset P; Lejeune JP; Lesoin F; Dhellemmes P; Jomin M; Christiaens JL; Dupont A
    Arch Anat Cytol Pathol; 1990; 38(3):81-5. PubMed ID: 2363592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 labelling index in human brain tumours.
    Niemiec J
    Folia Histochem Cytobiol; 2001; 39(3):259-62. PubMed ID: 11534782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
    Prayson RA; Mohan DS; Song P; Suh JH
    Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas.
    Zhen HN; Zhang X; Hu PZ; Yang TT; Fei Z; Zhang JN; Fu LA; He XS; Ma FC; Wang XL
    Cancer; 2005 Dec; 104(12):2775-83. PubMed ID: 16284993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
    Sakai K; Hongo K; Tanaka Y; Nakayama J
    Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.